Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in CNV due to PXE
NCT00510965Phase 2Completed
- Sponsor
- University Hospital Bonn
- Start
- Aug 2007
- Primary completion
- Apr 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in choroidal neovascularization (CNV), sponsored by University Hospital Bonn. Primary endpoint: Best Corrected Visual Acuity at 1 year. Started Aug 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT00510965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510965.